Efficacy and safety of antifibrotic drugs for interstitial lung diseases other than IPF: A systematic review, meta-analysis and trial sequential analysis.
<h4>Background</h4>The therapeutic role of antifibrotic therapy has been well-established in idiopathic pulmonary fibrosis (IPF). However, its efficacy and safety for interstitial lung diseases (ILDs) other than IPF are not fully understood.<h4>Methods</h4>We updated a system...
Saved in:
Main Authors: | Mei Yang, Yuying Tan, Ting Yang, Dan Xu, Mei Chen, Lei Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2025-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0318877 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Postoperative Acute Exacerbation of IPF after Lung Resection for Primary Lung Cancer
by: Atsushi Watanabe, et al.
Published: (2011-01-01) -
Role of IPF genetic risk loci in post-COVID-19 lung abnormalities: a cohort study
by: James Johnston, et al.
Published: (2025-01-01) -
The Role of Cardiopulmonary Exercise Test in IPF Prognosis
by: Christina Triantafillidou, et al.
Published: (2013-01-01) -
Antifibrotic Activity of Acylated and Unacylated Ghrelin
by: Elia Angelino, et al.
Published: (2015-01-01) -
The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects
by: Galina S. Bogatkevich, et al.
Published: (2012-01-01)